DHEERAJ HINDUJA'S PLANS FOR ASHOK LEYLAND

SEPTEMBER 2025 ▪ **FORTUNEINDIA.COM**

FORTUNE INDIA

PRICE ₹ 300

TATA SONS' FIVE-YEAR BLUEPRINT

U.S. TARIFFS AND THE ROAD AHEAD FOR INDIA

AUTO SPECIAL

THE YEAR OF EV LAUNCHES

WITH EV ADOPTION SURGING IN 2025, AUTO MAJORS SUCH AS TATA MOTORS AND M&M ARE GOING ALL OUT TO WOO BUYERS WITH NEW MODELS.

ANISH SHAH
Group CEO & MD,
Mahindra Group

RAJESH JEJURIKAR
ED & CEO, Auto and
Farm Sectors,
Mahindra & Mahindra


MISSION TO EARTH*PHASE*
Only available at selected Swatch stores

LORD'S MARK INDUSTRIES

REINVENTING GROWTH WITH PURPOSE

Sachidanand Upadhyay is the key promoter of Lords Mark Industries Ltd. A technocrat with an unwavering vision for growth, he leads the group from the front. Born on December 3, 1977, his educational foundation was laid at Vidya Mandir School in Dahisar. However, his entrepreneurial aspirations were ignited by the likes of Shri. Ratan Tata. Commencing his professional journey with M/s Ion Exchange (I) Ltd, Upadhyay garnered extensive experience through pivotal roles in renowned corporations such as Nutrients Confectionery, Hindustan Lever Ltd. and Blue Dart, before he ventured out on his own in 1998 with Lords Mark Industries. Upadhyay has since expanded the group's footprint into the Solar/LED industry, Healthcare, Automotive, and Innovative MedTech Sectors.

Sachidanand Upadhyay
MD & CEO, Lords Mark Industries Ltd.

With 27 years of legacy, Lord's Mark Industries has solidified its position as a prominent market player. As part of its strategic growth, the group has ventured into emerging sectors such as MedTech, Pharmaceuticals, Solar/ LED and biotech. They are also actively exploring global expansion opportunities. Under Upadhyay's leadership, the group has experienced exponential growth over the past decade, fostering an ecosystem that is attuned to technological advancements and evolving consumer needs. This approach is ingrained in the group's DNA, with value creation at the core of every decision.

The company's operations are spread across key business units - Renewable energy, healthcare, and medical diagnostic. Looking ahead, Lord's Mark Industries plans significant expansions into these sectors, with a vision to deliver value to all stakeholders and establish itself as a globally recognized brand in conglomerate industries.

SUNRISE SECTOR

a) Energy Consumption, Renewable energy

India's energy story is at a pivotal juncture. With demand surging from industry, urbanisation, and digitalisation, the choices we make today will define our nation's growth trajectory for decades to come. The transition from conventional fuels to renewable energy is not just about reducing carbon footprints; it is about ensuring long-term energy security, affordability, and global competitiveness.

What makes renewable energy a true sunrise sector is the confluence of policy support, falling technology costs, and unprecedented investor interest. Solar, wind, and bioenergy are no longer peripheral instead they are fast becoming mainstream contributors to our power mix. The government's ambition of achieving 500 GW of non-fossil capacity by 2030 is a bold but achievable goal, especially as innovations in storage and grid integration begin to unlock new efficiencies.

We see this as an opportunity to align business growth with national priorities. Clean energy will power industries, create millions of jobs, and deliver sustainable value to communities.

b) Medtech and diagnostic

India's healthcare sector is entering one of its most transformative phases. The expansion of hospitals, record investments, and universal access programs like Ayushman Bharat are laying the foundation for a healthier nation. Yet, what excites me most is the MedTech revolution. From being a market heavily dependent on imports, India is rapidly evolving into a global hub for medical technology innovation.

Valued at $12 billion today and projected to touch $50 billion by 2030, MedTech represents not just economic opportunity but also a chance to democratize healthcare. With PLI incentives, dedicated medical device parks, and world-class R&D centres, India is building the ecosystem to design, manufacture, and scale affordable solutions for millions. This is about leading it with accessibility and affordability at its core.

Our focus on diagnostics, biotechnology, and affordable medical solutions is aligned with India's larger healthcare transformation.

Reference link to verify data - https://www.ey.com/en_in/insights/health/india-s-medtech-transformation-paving-the-path-to-global-leadership?utm_source=chatgpt.com

c) Sickle cell

Sickle Cell Disease is one of India's most urgent public health challenges, especially in tribal and underserved communities. The Government's mission to eliminate it by 2047 underscores the scale and urgency of action required. Early screening, affordable diagnostics, and accessible treatment are the real levers of change.

This is where MedTech and biotech innovation can be transformative bringing advanced, point-of-care solutions to the grassroots. At Lords Mark Industries, we are committed to enabling this shift. Our partnership with IIT Bombay to advance rapid diagnostic solutions is a step in that direction, combining academic innovation with our manufacturing capabilities. Licensing their patented AI-enabled Point-of-Screening (POS) technology - Shape DX, represents a breakthrough. Delivered via a compact, microscopy-based device, it can distinguish healthy, carrier, and anaemic profiles within 30 minutes with unparalleled accuracy versus the usual 24–48-hour wait.

For us, addressing Sickle Cell goes beyond tackling a genetic disorder, it is about reducing health inequity, empowering vulnerable communities, and reinforcing India's healthcare inclusivity. The convergence of policy focus, technology, and private sector commitment positions India to turn this challenge into a milestone in public health leadership.

d) Dialysis Machine

Chronic Kidney Disease (CKD) is a silent epidemic in India, with prevalence rates increasing steadily over recent years. The demand for dialysis is escalating, yet access remains a significant challenge due to high costs and infrastructure gaps. A systematic review indicates that CKD prevalence among Indians aged 15 years and above has risen from 11.12% during 2011–2017 to 16.38% between 2018–2023. Notably, rural areas exhibit a higher burden, with 15.34% affected compared to 10.65% in urban regions. Addressing this requires a paradigm shift, one that combines affordability, accessibility, and technological innovation.

“By stepping into industries aligned with national priorities - be it clean energy or affordable healthcare - Lord's Mark has consistently ensured that growth is not only profitable but also purposeful.”

Renalyx Health Systems has pioneered this transformation with the launch of RxT21, India's first fully indigenous, AI-powered smart hemodialysis machine. Priced at ₹6.7 lakh, it is 20–25% more affordable than imported alternatives, making dialysis accessible to a broader population. The machine offers real-time remote monitoring and clinical connectivity, enabling telenephrology and reducing dropout rates by bringing care closer to patients' homes.

We recognize the critical need for such innovations. Our commitment to advancing healthcare technology aligns with the vision of making quality renal care accessible to all. The introduction of RxT21 is a significant step toward bridging the dialysis access gap in India, and we are proud to support and collaborate with initiatives that drive this change.

Reference link to verify data - https://pubmed.ncbi.nlm.nih.gov/39763170/

VISION

To transform Lord's Mark Industries into a globally recognized, innovation-driven conglomerate, delivering sustainable solutions across sectors like MedTech, renewable energy, and biotechnology, while creating enduring value for stakeholders and society.

COMPANIES PLAN & STRATEGY

Lord's Mark Industries is strategically positioning itself as a diversified global conglomerate with a strong emphasis on MedTech, diagnostics, renewable energy, and technology innovation. The company is set to debut on the Bombay Stock Exchange (BSE) following a reverse merger with Kratos Energy & Infrastructure Ltd., aiming to enhance operational synergies and expand its market presence. This move is part of a broader strategy to list on the National Stock Exchange (NSE) within the next six months, thereby increasing liquidity and attracting a wider investor base.

Financially, Lord's Mark Industries is targeting a revenue of ₹650 crore for FY25, with projections to reach ₹950 crore by FY26. The company plans to utilize the proceeds from its public offering to bolster its MedTech and diagnostics divisions, including the development of AI-powered medical devices and expansion of its in vitro diagnostics (IVD) manufacturing capabilities. While, Globally, Lord's Mark has established a presence in the U.S. through Lord's Global, securing a $1 million order for contactless remote patient monitoring systems. This expansion underscores the company's commitment to global growth and innovation in healthcare technology.

OUTPUT- INVESTORS & STAKEHOLDERS

Lord's Mark Industries offers a compelling investment proposition, combining diversified sector leadership with robust growth potential. With strategic focus areas in MedTech, diagnostics, renewable energy, and biotechnology, the company is poised for strong revenue expansion and scalable innovation. The upcoming public listing on the BSE, followed by NSE entry, provides transparency, liquidity, and access to a broader investor base. Backed by global partnerships, cutting-edge technology, and a visionary leadership team, Lord's Mark is committed to delivering consistent shareholder returns while driving meaningful societal impact. I reaffirm my commitment that we will continue to strategically invest in growth and innovation to unlock sustainable value for our stakeholders and partners, making Lord's Mark an attractive destination for investors seeking growth, innovation, and long-term value. ■